SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $529,120,900 |
| Positions | 42 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| ABIVAX SA | ABVX | SPONSORED ADS | $53,304,000 | 400,000 |
| VOR BIOPHARMA INC | VOR | COM NEW | $31,297,000 | 1,700,000 |
| ABIVAX SA | ABVX | SPONSORED ADS | $27,226,884 | 204,314 |
| IMMUNITYBIO INC | IBRX | COM | $26,272,004 | 3,000,800 |
| VERA THERAPEUTICS INC | VERA | CL A | $25,781,873 | 600,836 |
| ZURA BIO LTD | ZURA | CLASS A ORD SHS | $24,873,987 | 4,215,930 |
| ALUMIS INC | ALMS | COM | $24,089,557 | 856,061 |
| SOL-GEL TECHNOLOGIES LTD | Unresolved | SHS NEW | $20,341,273 | 274,363 |
| ULTRAGENYX PHARMACEUTICAL IN | RARE | COM | $20,034,000 | 600,000 |
| DEFINIUM THERAPEUTICS INC | DFTX | COM SHS | $19,992,000 | 425,000 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.